CJC-1295

Growth hormone–releasing hormone (GHRH) analog

What It Is

A synthetic peptide designed to mimic and extend the activity of growth hormone–releasing hormone, which stimulates the pituitary gland to release growth hormone. Exists in variants with and without a "drug affinity complex" (DAC) that extends its half-life — these variants should be distinguished when discussed, not treated as one compound.

Proposed Mechanism

Binds GHRH receptors in the pituitary to stimulate growth hormone release, similar to natural GHRH but with a longer duration of action than the native hormone.

Areas Researchers Are Investigating

• Growth hormone secretion dynamics
• Potential body-composition-related research questions (mostly community-driven interest rather than a deep clinical trial base)

Human Evidence

Limited public clinical trial data; most available human information comes from earlier-stage or smaller studies rather than large controlled trials of the kind supporting an FDA-approved product.

Animal / Preclinical Evidence

Growth-hormone-axis pharmacology research, with more extensive preclinical characterization than human data.

Current FDA / Regulatory Status

Not FDA-approved. Not available as an approved prescription product for any indication; commonly found in the gray-market "research chemical" space, which this business does not sell into.

Known Safety Information

No comprehensive, controlled human safety database exists publicly at the scale of an approved drug. Effects related to growth hormone elevation generally are an active research and clinical-monitoring topic that requires licensed medical oversight, not consumer self-guidance.

Limitations of Evidence

Sparse controlled human data; variant (with/without DAC) is often not clearly distinguished in available sources, which is itself a data-quality problem worth flagging in any article.